Navigation Links
InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
Date:11/5/2009

- Pirfenidone ----------- Submission of pirfenidone MAA to EMEA Q1 2010 ------------------------------------- ------- ITMN-191 (RG7227) ---------------- Rapid Virologic Response (RVR) data from Phase 2b (12-week regimens) Q1 2010 ------------------------------------------------- ------- Initiate INFORM-2 program Q1 2010 ------------------------- ------- Initiate longer duration INFORM studies to evaluate SVR H1 2010 --------------------------------------------------- -------

Guidance for 2009 Revenue and Expenses

The company updated its 2009 financial guidance for revenue and operating expenses from the guidance initially provided on February 26, 2009.

Revenue: 2009 revenue, including Actimmune® and milestone payments from Roche, is expected to be in a range of approximately $45 to $50 million. Actimmune revenue represents approximately 50 percent of this revenue range.

Operating Expenses


    -- R&D expense:  anticipated to be in a range of approximately $90 to $100
       million, net of development cost reimbursements under the Roche
       collaboration.  Of this amount, approximately 60 percent is attributed
       to pirfenidone which includes expenses for CAPACITY, RECAP, the
       preparation and support of NDA and MAA submissions and manufacturing.

       Approximately 35 percent of the R&D expense is attributed to the
       company's one-third share of all development expenses incurred by the
       collaboration with Roche on ITMN-191.  The balance of 2009 R&D expense
       is related to the advancement of a named pirfenidone analog compound,
       ITMN-520, 
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015 The role of the ... but one thing hasn,t changed: face-to-face meetings are seen ... with Key Opinion Leaders. Yet at the ... valuable type of interaction, field medical teams within the ... interactions. This is just one of the challenges addressed ...
(Date:2/27/2015)... YORK , Feb. 27, 2015  Pomerantz LLP ... Pharmaceuticals, Inc. ("Vitae" or the "Company") (NASDAQ: ... Robert S. Willoughby at rswilloughby@pomlaw.com or ... Vitae and certain of its officers and/or directors have ... Act of 1934.  On February 27, ...
(Date:2/27/2015)...  Acsis Inc., the market leader for supply chain ... John DiPalo , Acsis, Chief Strategy Officer, has ... Executive 2015 Provider Pro to Know. The award ... help prepare their companies, and customers, supply chains for ... list of Provider Pros to Know is featured in ...
Breaking Medicine Technology:Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2
... immunogenicity results for seasonal vaccine program follows positive results from ... plans to initiate a study of the seasonal vaccine in ... ROCKVILLE, Md., Dec. 11 Novavax, Inc. (Nasdaq: ... Phase IIa human clinical trial of its seasonal influenza VLP ...
... 11 ,Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN ... ) and Alkermes, Inc. (Nasdaq: ALKS ... Administration (FDA) recently indicated that the ongoing extension ... the basis for demonstrating,comparability between intermediate-scale clinical trial ...
Cached Medicine Technology:Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 2Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 3Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 4Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 5Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 6Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 2Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 3Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 4Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 5Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 6Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 7
(Date:2/28/2015)... 2015 Pioneer Millworks reclaimed USA wood ... & Construction Materials Show, an annual, premier sustainable building ... suppliers and top manufacturers of the latest building products, ... sourced and manufactured by Pioneer Millworks from their ... Japan at restaurants, hotels, retailers, and corporate offices. ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Kaylie Corrigan, ... alcohol treatment center , and current student obtaining her ... has implemented a weekly forum in psychoeducation on substance ... in Flagstaff, AZ as part of her studies. , ... need for support and counseling at the high school ...
(Date:2/28/2015)... February 28, 2015 Developers of FCPX ... a new overlay plugin for Final Cut Pro X entitled ... “FCPX Overlay Chromatic gives users total control over 6k lens ... CEO of Pixel Film Studios. “FCPX Overlay Chromatic was professionally ... to use interface.” , FCPX Overlay Chromatic Grunge 6K is ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The World ... and learning materials to potential EMTs and firefighters, recently ... Bitcoins as a way to raise charitable donations for ... in Medellin, Columbia, will be held on March 29, ... run will begin at 3:30 p.m. , To ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 OnChip ... (IPD), has introduced miniature, wire bondable, silicon ESD (Electrostatic ... LED markets. The ESD88NP and ... away from sensitive LED and IC products. These ... Varistors (MLV). All devices meet the requirements of ...
Breaking Medicine News(10 mins):Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3
... York have achieved a breakthrough of sorts in cancer ... to a key position on cancer cells and gives ... of advanced colorectal cancer patients. ,IMC-C225, the new ... to interfere with the epidermal growth factor receptor, a ...
... is one of the worst types of chronic pain. ... painful condition. But now there’s good news for the ... the most popular forms of alternative medicine, is supposed ... ,A team led by Dr. Jeanette Ezzo, Washington, ...
... of the journal Epidemiology, high levels of DDT found in ... function. The human body metabolises DDT to DDE. An international ... 16 to 28 who had not been exposed to DDT ... levels correlated to low levels of testosterone, low semen volume ...
... Millions of postmenopausal women suffer from sexual dysfunctions- ... physiological and psychological problems. ,However if the ... these problems can be treated properly. Almost all ... develop changes in genital organs-particularly a condition known ...
... in four countries have unanimously opined that the deadly ... from an oral polio vaccine used in Africa in ... no scientific evidence to back them up. ,The ... Germany, should help free the polio vaccine manufactured by ...
... Thursday that plans are afoot to consider listing on US ... bourses after 2002," Pratap C Reddy, chairman of the Apollo ... business plan for the post-2002 period. ,Though further details ... plans to raise the number of beds to 8000 from ...
Cached Medicine News:
... all those involved with healthcare decisions to ... latest evidence in their field of interest ... year as the volume of evidence increases. ... the best single source available for continually ...
... CVMstat® provides leading ... of topics involving all ... including sections on diagnosis ... arterial and venous disease. ...
... to the management of common ... a response from leading experts ... more common, and often poorly ... It is a "how-to" guide ...
The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan...
Medicine Products: